Sun Pharmaceutical Industries Limited announced its audited financial results for the quarter and year ended 31 March 2026, alongside a recommendation for a final dividend of Rs. 5/- per equity share of Re. 1/- each, subject to shareholder approval at the 34th Annual General Meeting. The company reported a significant consolidated net profit of Rs. 2,714 crore for the fourth quarter, representing a 26% year-on-year increase compared to Rs. 2,149 crore in the same period last year. Revenue for the quarter reached Rs. 145,598 million, reflecting a 13.6% growth year-on-year.

Note: The financial data provided in the notice is in Millions; the table above converts these figures to Crores for consistency (10 Million = 1 Crore).

Sun Pharmaceutical Industries Limited is the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company globally. The company operates a vast business, ranging from producing generics, branded generics, specialty, over-the-counter (OTC) products, and anti-retrovirals to active pharmaceutical ingredients (APIs) across a wide range of dosage forms. Throughout 2025, the company engaged in strategic growth initiatives, including the completion of its acquisition of Checkpoint Therapeutics, which added an FDA-approved anti-PD-L1 treatment to its portfolio. Additionally, Sun Pharma entered into collaborations to improve care for hyperkalaemia patients and expanded its US presence with the launch of LEQSELVI tablets. As of February 2025, the company was recognized for its ESG commitments, ranking among the top 5% of pharmaceutical companies globally in the S&P Global Sustainability Yearbook 2025.